BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28623515)

  • 1. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
    Marsh Rde W; George T
    Curr Gastroenterol Rep; 2006 Apr; 8(2):111-20. PubMed ID: 16533473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.
    O'Reilly EM; Cockrum P; Surinach A; Wu Z; Dillon A; Yu KH
    Cancer Med; 2020 Nov; 9(22):8480-8490. PubMed ID: 32997898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
    Bisht S; Brossart P; Feldmann G
    Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Ogden JR; Yin J; Jatoi A; Hubbard JM; McWilliams RR; Mahipal A; Petersen GM; Bekaii-Saab TS; Ma WW
    Am J Clin Oncol; 2020 Aug; 43(8):586-590. PubMed ID: 32349022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    Lemstrova R; Melichar B; Mohelnikova-Duchonova B
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma.
    Mitsunaga S; Kasamatsu E; Machii K
    Support Care Cancer; 2020 Nov; 28(11):5271-5279. PubMed ID: 32103356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.
    Kamgar M; Chakrabarti S; Shreenivas A; George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):673-691. PubMed ID: 34511189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option.
    Argentiero A; Calabrese A; Sciacovelli AM; Delcuratolo S; Solimando AG; Brunetti O
    Can J Gastroenterol Hepatol; 2020; 2020():8679751. PubMed ID: 33102398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.